0001209191-23-050305.txt : 20230921
0001209191-23-050305.hdr.sgml : 20230921
20230921171006
ACCESSION NUMBER: 0001209191-23-050305
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230919
FILED AS OF DATE: 20230921
DATE AS OF CHANGE: 20230921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Katabi Maha
CENTRAL INDEX KEY: 0001720685
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41799
FILM NUMBER: 231269730
MAIL ADDRESS:
STREET 1: SOFINNOVA INVESTMENTS
STREET 2: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RayzeBio, Inc.
CENTRAL INDEX KEY: 0001825367
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (619) 937-2754
MAIL ADDRESS:
STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-19
0
0001825367
RayzeBio, Inc.
RYZB
0001720685
Katabi Maha
C/O RAYZEBIO, INC.
5505 MOREHOUSE DRIVE, SUITE 300
SAN DIEGO
CA
92121
1
0
0
0
0
Common Stock
2023-09-19
4
C
0
973653
A
973653
I
See footnote
Common Stock
2023-09-19
4
C
0
973653
A
973653
I
See footnote
Common Stock
2023-09-19
4
P
0
236111
18.00
A
1209764
I
See footnote
Common Stock
2023-09-19
4
P
0
236111
18.00
A
1209764
I
See footnote
Series D Convertible Preferred Stock
2023-09-19
4
C
0
973653
D
Common Stock
973653
0
I
By Sofinnova Venture Partners X, L.P.
Series D Convertible Preferred Stock
2023-09-19
4
C
0
973653
D
Common Stock
973653
0
I
By Sofinnova Venture Partners XI, L.P.
Every 5.141 shares of Series D Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
The shares are held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.P. ("SM X LP"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. ("SM X LLC"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
The shares are held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. ("SM XI LLC"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
The shares were purchased in the Issuer's initial public offering.
/s/ Jeff Woodley, Attorney-in-fact
2023-09-21